Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 5,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Polycythemia Vera
Interventions: Ruxolitinib, Hydroxyurea (HU), HU-placebo, Ruxolitinib-placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 51
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Burbank, California + 48 more

Conditions: Carcinoid Syndrome
Interventions: Telotristat etiprate, Octreotide LAR Depot, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 9
States / cities: Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more

Conditions: Vasomotor Symptoms (VMS)
Interventions: Q-122, Placebo; Drug
Lead sponsor: Que Oncology; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Woodstock, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 3 more

Conditions: Sickle Cell Anemia, Sickle Cell-Beta0-Thalassemia
Interventions: rivaroxaban, placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Endometrial Hyperplasia, Osteoporosis
Interventions: Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 1,083 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 9
States / cities: Upland, California • Inverness, Florida • West Palm Beach, Florida + 6 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: NVA237, Long-acting beta 2-agonist (LABA), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 61
States / cities: Gulf Shores, Alabama • Mobile, Alabama • Tucson, Arizona + 52 more

Conditions: Steatohepatitis
Interventions: Placebo capsule, EPA-E 300 mg capsule; Drug
Lead sponsor: Mochida Pharmaceutical Company, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 33
States / cities: Dothan, Alabama • Tucson, Arizona • Anaheim, California + 27 more

Conditions: Hypogonadism
Interventions: TSX-002; Drug
Lead sponsor: TesoRx Pharma, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Generalized Anxiety Disorder (GAD)
Interventions: ABBV-932, Placebo for ABBV-932, Antidepressant Therapy (ADT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 49
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium, Combivent (Ipratropium/Albuterol); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
Interventions: MitoQ (mitoquinol mesylate), Placebo; Drug · Other
Lead sponsor: Iman Al-Naggar, PhD; Other
Eligibility: 50 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Thyroid Cancer
Interventions: Lenvatinib, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 38
States / cities: Little Rock, Arkansas • La Jolla, California • Los Gatos, California + 30 more

Conditions: Healthy
Interventions: fluoxetine HCL 40 mg capsules; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Psychosis Associated With Alzheimer's Disease
Interventions: KarXT, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 70
States / cities: Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 43 more

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: forodesine HCl; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: Beverly Hills, California • Los Angeles, California • Indianapolis, Indiana + 5 more

Conditions: Ureteral Calculi
Interventions: celecoxib, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Gastroesophageal Reflux
Interventions: rabeprazole sodium; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Prostate Cancer
Interventions: Gefitinib plus etoposide; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157 or Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: South Miami, Florida

Conditions: Diabetes Type 2, Diabetes Mellitus
Interventions: WB-011, Placebo, Continuous Glucose Monitor; Other · Device
Lead sponsor: Pendulum Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Post-Traumatic Headache
Interventions: Prazosin, Placebo; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Cocaine Use
Interventions: l-tetrahydropalmatine (l-THP), Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Healthy
Interventions: Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg, Macrobid® Capsules 100 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Osteoarthritis, Osteo Arthritis Knee
Interventions: Colchicine 0.8 mg or 0.6 mg orally once daily, Placebo oral capsule; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

The Effect of Rivaroxaban in Sickle Cell Disease

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)

Oral Testosterone for the Treatment of Hypogonadism

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.

Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

Celecoxib (Celebrex) in the Management of Acute Renal Colic

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients

Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study

Prazosin for Post-Concussive Headaches

L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder

Fed Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg

Colchicine for the Treatment of Osteoarthritis of the Knee